The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $6.26 in the prior trading day, Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) closed at $6.33, up 1.12%. In other words, the price has increased by $1.12 from its previous closing price. On the day, 0.77 million shares were traded. ARCT stock price reached its highest trading level at $6.38 during the session, while it also had its lowest trading level at $6.07.
Ratios:
Our goal is to gain a better understanding of ARCT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 7.86. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On October 23, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 179851344 and an Enterprise Value of 25478360. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.11 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 0.261 whereas that against EBITDA is -0.339.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.18, which has changed by -0.63024217 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $24.17, while it has fallen to a 52-week low of $5.85. The 50-Day Moving Average of the stock is -57.22%, while the 200-Day Moving Average is calculated to be -54.86%.
Shares Statistics:
The stock has traded on average 1.23M shares per day over the past 3-months and 1031950 shares per day over the last 10 days, according to various share statistics. A total of 27.23M shares are outstanding, with a floating share count of 26.02M. Insiders hold about 8.42% of the company’s shares, while institutions hold 84.63% stake in the company. Shares short for ARCT as of 1761868800 were 6948548 with a Short Ratio of 5.65, compared to 1759190400 on 5143436. Therefore, it implies a Short% of Shares Outstanding of 6948548 and a Short% of Float of 39.380002.
Earnings Estimates
The market rating for Arcturus Therapeutics Holdings Inc (ARCT) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.43, with high estimates of $0.08 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$1.49 and -$2.64 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$2.51, with 9.0 analysts recommending between $0.49 and -$4.4.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $6.85M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $3.7M.
A total of 10 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $104.33M, while the lowest revenue estimate was $74.83M, resulting in an average revenue estimate of $90.41M. In the same quarter a year ago, actual revenue was $152.31MBased on 11 analysts’ estimates, the company’s revenue will be $67.88M in the next fiscal year. The high estimate is $173.94M and the low estimate is $14.6M.
